INTERMITTENT ANDROGEN DEPRIVATION THERAPY IN THE ERA OF ANDROGEN RECEPTOR PATHWAY INHIBITORS; A PHASE 3 PRAGMATIC RANDOMISED TRIAL

Informazioni relative al progetto

DE-ESCALATE

ID dell’accordo di sovvenzione: 101104574

DOI

10.3030/101104574

Data della firma CE 21 Aprile 2023

Data di avvio 1 Giugno 2023

Data di completamento 31 Maggio 2028

Finanziato da

• Health

Costo totale

€ 7 185 663,75

Contributo UE

€ 7 185 663,00

Coordinato da

EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL
Belgium

CORDIS fornisce collegamenti ai risultati finali pubblici e alle pubblicazioni dei progetti ORIZZONTE.

I link ai risultati e alle pubblicazioni dei progetti del 7° PQ, così come i link ad alcuni tipi di risultati specifici come dataset e software, sono recuperati dinamicamente da .OpenAIRE .

Risultati finali

Documents, reports (5)

Plan for dissemination and exploitation

The plan that will describe project strategy for communication and dissemination

Conclusions of common annual meeting of the ‘Diagnosis and treatment’ cluster 1

Conclusions of common annual meeting of the ‘Diagnosis and treatment’ cluster

Policy brief 1

Policy brief formulating recommendations based on the research and innovation strand of the ‘Diagnosis and treatment’ annual cluster meeting

Data Management Plan

The DMP will describe which data/variables are collected, the standards used, how they are processed and stored and how they could be accessed.The preparation of the Data Management Plan will include a common chapter on the ‘Diagnosis and treatment’ cluster. The aim is of the chapter is to address commonalities in data standards, data validation, data protection and foster data exchange.

Initial common work plan for scientific collaboration under the ‘Diagnosis and treatment’ cluster

Other (1)

Project website is online

launch of the project dedicated public website

Pubblicazioni

Peer reviewed articles (1)

"EORTC 2238 ""De-Escalate"": a pragmatic trial to revisit intermittent androgen deprivation therapy in the era of new androgen receptor pathway inhibitors."

Autori: Grisay G, Turco F, Litiere S, Fournier B, Patrikidou A, Gallardo E, McDermott R, Alanya A, Gillessen S, Tombal B
Pubblicato in: Frontiers in oncology, 2024, ISSN 1664-3224
Editore: Frontiers media
DOI: 10.3389/FONC.2024.1391825

Conference proceedings (1)

EORTC GUCG 2238 De-escalate: A pragmatic trial to revisit intermittent androgen-deprivation therapy in metastatic hormone-naïve prostate cancer in the era of new AR pathway inhibitors.

Autori: Guillaume Grisay, Fabio Turco, Anna Patrikidou, Enrique Gallardo Díaz, Raymond S. McDermott, Saskia Litiere, Beatrice Fournier, Silke Gillessen, and Bertrand F. Tombal
Pubblicato in: Journal of Clinical Oncology, 2024, ISSN 0732-183X
Editore: American Society of Clinical Oncology
DOI: 10.1200/JCO.2024.42.4_suppl.TPS2